A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric Cancer).

The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients/subjects with advanced gastric cancer.

Inclusion Criteria:
• Advanced Gastric Cancer
• Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work
• Must have at least 1 lesion with measurable disease

Exclusion Criteria:
• Patients/subjects with HER2 positive tumor that have not been treated with trastuzumab prior to enrollment
• Must not have suspected or known central nervous system metastases unless adequately treated
• Patients/subjects with autoimmune disease
• Patients/subjects who need daily oxygen therapy

Phase II
Gina Vaccaro, M.D.
BMS (Bristol-Myers Squibb)
Mary Mccormick
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic